

Prof_hatta.pdf

by

FILE	PROF_HATTA.PDF (735.03K)	WORD COUNT	4383
TIME SUBMITTED	24-NOV-2020 09:16AM (UTC+0700)	CHARACTER COUNT	23362
SUBMISSION ID	1455633562		

Journal Pre-proofs

The Correlation of Foxp3+ Gene and Regulatory T Cells with Scar BCG Formation among Children with Tuberculosis

Farsida, Mochammad Hatta, Ilhamjaya Patellongi, Prihantono, Rahmini Shabariyah, Rahma Ayu Larasati, Andi Asadul Islam, Rosdiana Natzir, Muh. Nasrum, Firdaus Hamid, Andi Dwi Bahagia

PII: S2405-5794(20)30066-8
DOI: <https://doi.org/10.1016/j.jctube.2020.100202>
Reference: JCTUBE 100202


To appear in: *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*

Received Date: 22 October 2020
Accepted Date: 10 November 2020

Please cite this article as: Farsida, M. Hatta, I. Patellongi, Prihantono, R. Shabariyah, R. Ayu Larasati, A. Asadul Islam, R. Natzir, Muh. Nasrum, F. Hamid, A. Dwi Bahagia, The Correlation of Foxp3+ Gene and Regulatory T Cells with Scar BCG Formation among Children with Tuberculosis, *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases* (2020), doi: <https://doi.org/10.1016/j.jctube.2020.100202>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 The Author(s). Published by Elsevier Ltd.



The Correlation of Foxp3+ Gene and Regulatory T Cells with Scar BCG Formation among Children with Tuberculosis

Farsida¹, Mochammad Hatta², Ilhamjaya Patellongi², Prihantono², Rahmini Shabariyah¹, Rahma Ayu Larasati¹, Andi Asadul Islam², Rosdiana Natzir², Muh. Nasrum², Firdaus Hamid², Andi Dwi Bahagia²

¹ Faculty of Medicine, Universitas Muhammadiyah Jakarta;

² Faculty of Medicine, Universitas Hasanuddin Makassar;

* Correspondence: dr.larasatirahma@gmail.com ;

‡ These authors contributed equally to this work.

Abstract: Tuberculosis infection causes a complex immunological response, where interactions between the pathogen and the host are unique, making it difficult to treat and control this disease. According to WHO, an estimated 1 million children became ill with TB, and 233,000 children died of TB in 2017. Bacillus Calmette-Guérin (BCG) vaccines continue to be the only vaccines to prevent Tuberculosis (TB). Studies suggesting the association of BCG scar with decreased childhood mortality in developing countries have rekindled the interest in BCG scar. However, the direct effect of the BCG scar remains unknown. We examined 76 cases in this study. All Subjects were diagnosed with Tuberculosis. BCG scars were examined directly when physical examination at the BCG vaccination site was performed. Tuberculin Skin Test was performed with 0.1 ml purified protein derivative (PPD) solution (5TU PPD/0.1 ml) injected intradermally. We examined the FOXP3 gene with real-time PCR and the level of Treg with ELISA. The comparison of the mean Treg gene expression and the Treg protein content was higher in the positive scar group than in the negative scar group. It shows that Treg plays a role in the Tuberculosis during its active phase development. Treg protein levels were higher in the combination of positive TST and scar. It shows that BCG scarring is an essential marker of a well-functioning immune system. Cheap and straightforward initiatives like early BCG vaccinations, monitoring BCG scarring, and revaccinating scar-negative children could have an enormous immediate impact on global child survival.

Keywords: Tuberculosis, BCG Scar, FOXP3, TREG

1. Introduction

Tuberculosis is a disease caused by the Mycobacterium Tuberculosis (Mtb). For thousands of years, humans have been infected with Mtb. This infection causes a complex immunological responses, where interactions between the pathogen and the host are unique, making it difficult to treat and control this disease. People of low economic backgrounds often contract the disease, thus worsening social and economic conditions. Although TB is a treatable infectious disease, it still has a high effect on mortality. TB is responsible for one in four deaths in the 19th century because of its chronic progressive transmission nature and prolonged treatment. Besides, the emergence of multi-drug resistant TB and the TB epidemic - putting a significant burden on society.

According to WHO, an estimated 1 million children became ill with TB, and 233,000 children died of TB in 2017. However, the actual burden of TB in children is likely higher, given the challenge in diagnosing childhood TB. Although overdiagnosis does occur in some settings, underdiagnosis is the rule in most TB-endemic areas, where young children can only access TB care via referral hospitals. Only 23% of the estimated 1.3 million children under five years

who are eligible received preventive therapy in TB households in 2017. Ending the TB epidemic is a target under the Sustainable Development Goals that requires implementing a mix of biomedical, public health targets, socioeconomic interventions, and research and innovation [1]. Understanding the natural history of TB is fundamental to appreciate the variable vulnerability, and the diverse spectrum of disease observed in children.

Bacillus Calmette-Guérin (BCG) vaccines continue to be the only vaccines in use for the prevention of Tuberculosis (TB). The use of BCG in routine infant vaccination programs (estimated coverage at 90%) is estimated to globally prevent 117,132 TB deaths per birth cohort in the first 15 years of life [1]. However, BCG affords variable efficacy against pulmonary TB. There has been much debate regarding the advantages and disadvantages of BCG since its first introduction. Key elements of the debate surrounding BCG's effectiveness have included safety, loss of tuberculin sensitivity as a diagnostic tool, and, especially, the broad range of BCG effectiveness against TB. Studies suggesting the association of BCG scar with decreased childhood mortality in developing countries have rekindled BCG scar's interest. But the direct effect of BCG scar still unknown [2–4].

This study is to get the correlation between regulatory T (T reg) cells in children with Tuberculosis. We looked for an association with the presence or absence of BCG scars and tuberculin test results. Regulatory T cells protect the host during infections by preventing collateral damage to the host's tissue from excessive inflammation induced by the immune response to the pathogen. The T reg cell's role in suppressing immunity to *Mtb*, which is the most important bacterial pathogen that establishes a persistent infection in humans in terms of morbidity and mortality, is only the early stage of an investigation.

2. Results

General Characteristic of Study Population

Based on the research subject, male 40 (52.6%) make up most of the population. Most re those at the age of 0-5 years by 41 people (53.9%). Poor nutrition 44 people (54.8%). Patient with contact history with adult TB was 39 (51.3%). Most of the TST tests were positive (>10mm) as many as 40 people (62.6%). Most of the scar marks were positive in 47 people (61.8%).

Table 1. General Characteristic of Subjects

Characteristic		N	%
Sex	Female	36	47,4%
	Male	40	52,6%
Age Group	0-5	41	53,9%
	6-12	24	31,6%
	12-18	11	14,5%
Nutritional Status	Malnutrition	44	57,9%
	Normal	32	42,1%
Contact History	No Contact	37	48,7%
	Positive Contact	39	51,3%
TST	<10	36	47,4%
	>10	40	52,6%
Scar	+	48	63,2%
	-	28	36,8%

The Level of FOXP3 Gene and Treg Serum Based on Scar Formation

The mean comparison of Foxp3 expression and Treg protein content was higher in the positive scar group than in the negative scar group.

Table 2. The Level of FOXP3 Gene and Treg Serum Based on Scar Formation

Parameter		N	Mean	SD	Min	Max
FoxP3+ Gene Expression	Scar -	29	7,790	1,582	5,330	10,804
	Scar +	47	11,681	1,679	9,191	14,815
Kadar serum Treg	Scar -	29	216,539	24,443	178,428	270,407
	Scar +	47	278,209	24,681	234,189	326,607




Figure 1. A. Comparison of FOXP3 expression B. Comparison level of T Reg based on Scar formation.

The Expression of FOXP3 gene and Level of Treg based on TST Result

The mean comparison of the Foxp3 gene and the level of Treg was higher in the positive TST group.




Figure 2. The Expression of FOXP3 gene and Level of Treg based on TST Result




Figure 3. The Comparison Level of T Reg Based on Scar Formation and TST Result

The results of the comparison test showed that there was a significant difference in the mean protein content of Foxp3 expression, between the Scar (+) TST (+) ($12,570 \pm 1,508$), Scar(+) TST(-) ($10,580 \pm 1,158$), and Scar(-) TST(+) groups ($8,936 \pm 1,326$). and Scar - mantox - ($6,860 \pm 1,098$) with a significant value of $p < 0,000$

The test results on the mean Treg protein levels showed a significant difference between Scar (+) TST (+) ($291,885 \pm 20,780$), Scar(+) TST(-) ($261,277 \pm 17,807$), Scar (-) TST (+) ($231,632 \pm 23,359$) and Scar (-) TST(-) ($204,275 \pm 17,912$) with a p value of 0.000




Figure 4. The Comparison Of FOXP3 Expression Based on Scar Formation and TST Result

3. Discussion

Characteristic of Study Population

We conducted a study on 76 subjects consisting of 40 males and 36 females. All the subjects received the BCG vaccine in two months of age. All the subjects had been diagnosed with Tuberculosis and confirmed with scoring and thorax Rontgen. Most subjects (N: 41) were diagnosed with Tuberculosis in 0 – 5 years of age. Forty-seven of subjects has BCG scar in the deltoid area from one of their arm. Thirty-nine subjects had TB history in their family. Forty-four of the population study has malnourished nutritional status.

Correlation of BCG Scar with Tuberculosis

BCG scar reading has been used as an indicator of vaccine status and became standard practice for assessing BCG's protective effect in retrospective studies. The presence of a BCG scar has been an indication of the protection against TB. Nevertheless, more than fifty percent of the study population with BCG scar got infected with TB in this case.

However, scars may be present or not after the BCG vaccine. Scars may be absent due to administrating lower doses of vaccine in childhood, the difficulty of injecting the entire amount of vaccine and the relatively weak local immune response in young children, or the probability that they may even disappear with time [5–7].

Several explanations have been put forward concerning such variability, including the improper handling and administration of the vaccine, exposure to non-tuberculous mycobacteria (NTM) in the per equatorial region, low immunogenicity of the vaccine, concomitant malnutrition, and other infectious diseases as well as a genetically determined low immune response to the vaccine [8–10].

In the present study, the absence of scarring on those who received vaccination may have influenced the effectiveness. This is because the vaccinated children who did not develop a scar (if, for example, the vaccine no longer contained live BCG due to inadequate storage) may have been considered unvaccinated, thus generating a non-

differential misclassification, which could minimize the protective effect of the vaccine.

Based on previous findings, the ability of BCG to induce scars may vary by sex, but the direct effect of sex still unknown [11]. There was also no significant difference between the age groups. Tuberculosis mostly affects adults in their most productive years. However, all age groups are at risk. Over 95% of cases and deaths are in developing countries. The observed effects of age, sex, and origin may reflect a combination of the effects of various host and microbial factors not included in the present study. All groups have the same risks. Age 0 – 5 have a longer time being contacted by their parents because they spent their activity at home. We knew that transmission rates due to direct contact with family are relatively high. In conjunction with recent findings, household-based contact interventions that include treatment of latent infections may prevent disease progression in young contacts of index patients in settings with a high tuberculosis burden [12–14].

Genetic and environmental factors also influence differences in the shape and size of scars. It is evidence in Lalor et al.'s research results in two populations that have genetic and microbial environmental differences between Malawi and England. In this study, the scar size that appeared after three months after BCG vaccination in the Malawian population was smaller than the median scar size in the UK population [9].

Correlation Level of Treg and FOXP3 with Scar BCG

Reports are pointing out that Tregs could interfere with BCG-mediated protection against TB. Tregs are known to be induced by environmental mycobacteria, BCG, and *M. tuberculosis* infection. Pre-exposure of the host to environmental mycobacteria may induce Tregs against antigens, typical to environmental mycobacteria, BCG, and *M. tuberculosis*. Such sensitized Tregs may further be stimulated by subsequent vaccination with BCG and by *M. tuberculosis* infection. Thus, Tregs induced first by environmental mycobacteria may initiate the process leading towards downmodulation of the BCG vaccine's efficacy. However, there may be scanty pre-induced Tregs available for stimulation by BCG vaccination when there are no environmental mycobacteria. In Treg-attenuated, BCG-immunized mice, which were then infected with *M. tuberculosis*, the mycobacterial lung load was significantly [6,11,15]

To evaluate Treg's impact in protection against *M. Tuberculosis*, we evaluate the expression of Treg and foxp3 in children with Tuberculosis. There is a significant difference between the two groups. A group with scar positive has a bigger account in

treg and foxp3. The Presence of scars after BCG vaccination has been used as an indicator of vaccination success and in estimating vaccine coverage. Indeed, the presence of a scar does not always correlate with protection against TB; however, it may reflect the efficacy BCGs against TB. Among BCG vaccinated individuals, having a scar is associated with further reduced mortality because of TB. Subjects with BCG scar have a higher amount of Treg and FOXP3 gene. It shows that Treg plays a role in the development of Tuberculosis in its active phase.

Correlation Level of Treg and FOXP3 with Tuberculin SkinTest

Short of demonstrating viable organisms in body tissues and fluids, the tuberculin skin test is the only method of detecting *M. tuberculosis* infection in an individual. It is used in the diagnosis of Tuberculosis in individual patients and in epidemiological settings to measure the prevalence of tuberculous infection in populations [16,17].

We use more than 10 mm as positive results for this study. There are exact amounts between positive and negative results [18]. Twenty-one (50%) subjects have positive results. So it means 50% of subjects have false-negative results. The Mantoux test does not measure immunity to TB but the degree of hypersensitivity to tuberculin. There is no correlation between the size of the induration and the likelihood of current active TB disease, but the reaction size is correlated with the future risk of developing TB disease. The test has a low positive predictive value for the current active disease [19,20].

In this study, we did not examine the direct impact of T regulatory cells against TB. In this study, we see significant differences in the level of T reg between each Mantoux group. There is a higher level in the group with more significant TST results in diameter. Active TB is characterized by increased Treg and decreased Th1 responses, which contribute to the establishment of active infection. However, the roles of Treg and Th1/Th2/Th17 cells in latent TB have not been elucidated [21].

4. Materials and Methods

The Selection of Study Population

This Cross-Sectional study was carried out at the Bhakti Medicare Hospital, Cicurug

West Java, Indonesia, ⁸ after obtaining permission from the Institutional Ethics Committee. Our subjects are ⁸ the infants recruited for the study from July to December 2019. The analysis of Treg and mRNA expression was held at The Molecular and Biology Laboratory Universitas Hasanuddin, Makassar South Sulawesi, Indonesia. ⁸ Only those children whose parents consented to participate in the study were recruited. A total of 76 cases were included by the method of purposive sampling. All Subjects were diagnosed with Tuberculosis by anamnesis, physical examination, tuberculin skin test, and thorax Rontgen. The 2 ml of whole blood was taken from each subject. The blood is taken before any use of medication.

BCG scars are examined directly when physical examination at the BCG vaccination site is performed. Tuberculin skin test was done with 0.1 ml purified protein derivative (PPD) solution (5TU PPD/0.1 ml, SPAN diagnostic limited) injected intradermally with a 26-Gauge needle on ²² the flexor aspect of the left forearm 2 to 3 inches below the elbow. Tuberculin skin test was read after 48 to 72 hours by a ballpoint pen technique. ³ We followed national guidelines for the diagnosis of active TB cases. A TB case was considered to be a child with *M. tuberculosis* isolated from clinical specimens, or with the presence of symptoms, signs, and/or radiological images compatible with TB (when chest radiography was doubtful, thoracic computed tomography was performed), and/or a positive TST (as defined previously), and who responded clinically to antituberculous chemotherapy. Close contact with a bacillary TB case was used as diagnostic support.

This study's exclusion criteria are HIV-positive or have a history of HIV parents, recent contacts of active tuberculosis cases, children with old healed TB, under immune-suppressive agents medication, and ⁵ patients on long-term systemic corticosteroid therapy (> than six weeks).

The Examination of FOXP3 gene with Real-time PCR

The process of examining the primary oligonucleotide specific gene for beta-actin (β actin) as the forward primary: CCACTGTGCCCATCTACGA and reverse primer: GTTTCATGGATGCCACAGGA as 'housekeeping gene' (internal control). How to detect the HGMB1 mRNA gene using a specific primer forward 5 '- GGAGGAGCAATAAGAAGAAGC-3' and Reverse 5 '- CATCTTCCTCCTCTTCCTTC - 3'. PCR protocol carried out DNA replication with a 94oC cycle for 3 minutes. The cycle was repeated 38 times with 94oC (30 seconds) and reverse primer: CATCTTCCTCCTCTTCCTTC following the Zetterström CK protocol. (Zetterström

CK.et.al., 2006). Real-time reverse transcription-PCR (QRT-PCR) process using Green QRT-PCR master mix kit, one stage.

The Examination of Treg with ELISA

The first step is to add 100 μ L assay diluent containing buffer protein to each well. Next, 100 μ L of standard liquid containing recombinant human protein TReg from the specified KIT or diluted sample from the patient's serum into each well was added. Furthermore, incubation was carried out for 2 hours at room temperature. Flush the liquid in each well and wash it with sterile Phosphate Buffered Saline (PBS). This washing process is carried out four times in a row. Then 200 μ L of the "conjugate" liquid containing "horseradish peroxidase" (HRP) streptavidin (HRP) was added to each well and covered with plastic cover and incubated for 2 hours at room temperature. The liquid is sucked and then washed again as much as four times using a sterile PBS liquid. The next process was adding 200 μ L of a substrate solution containing 3,3', 5,5' - Tetramethylbenzidine (TMB) to each well, and incubated for 20 minutes at room temperature. The microplate was kept in the dark to avoid light. After incubation, the reaction was stopped by adding 50 μ L of a stopping solution containing H₂SO₄ into each well and reading it using ELISA Reader 270 (Biomérieux, France) with a wavelength of 450 nm in 30 minutes. Next, read CD25 concentrations in pg / ml units.

Statistic Analysis

Statistical analysis used the Chi-square test to determine the association between BCG scar and tuberculin skin test and the association between BCG scar and various factors. The statistical testing results, a P value less than 0.05, were considered statistically significant in the relationship between the two variables. Statistical analysis was performed using Microsoft Excel and SPSS Statistical Software.

5. Conclusions

The expression of Treg gene mRNA was higher in the positive scar combination of positive Mantoux compared to other combinations. Treg protein levels were higher in the combination of positive Mantoux scar. BCG scarring is an important marker of a well-functioning immune system. Cheap and straightforward initiatives like early BCG vaccinations, monitoring BCG scarring, and revaccinating scar-negative children could have an enormous immediate impact on child survival worldwide.

References

1. WHO. Children and Adolescent TB. <https://www.who.int/tb/areas-of-work/children/en/>. 2018.
2. Van-Dunem JCVD, Rodrigues LC, Alencar LCA, Militão-Albuquerque M de FP, Ximenes RA de A. Effectiveness of the First Dose of BCG against Tuberculosis among HIV-Infected, Predominantly Immunodeficient Children. *BioMed Research International*. 2015;2015:1–10.
3. Shann F. Nonspecific Effects of Vaccines and the Reduction of Mortality in Children. *Clinical Therapeutics*. 2013 Feb;35(2):109–14.
4. Tavares Cruz C, Almeida B, Troster E, Oliveira C. Systematic Review of the Non-Specific Effects of Bacillus Calmette-Guérin Vaccine on Child Mortality. *J Infect Dis Treat [Internet]*. 2017 [cited 2020 Oct 3];03(02). Available from: <http://infectious-diseases-and-treatment.imedpub.com/systematic-review-of-the-nonspecific-effects-of-bacillus-calmetteguerin-vaccine-on-child-mortality.php?aid=21616>
5. Amaruddin AI, Wahyuni S, Hamid F, Chalid MT, Yazdanbakhsh M, Sartono E. BCG scar, socioeconomic and nutritional status: a study of newborns in urban area of Makassar, Indonesia. *Trop Med Int Health*. 2019 Jun;24(6):736–46.
6. Dhanawade S, Kumbhar S, Gore A, Patil V. Scar formation and tuberculin conversion following BCG vaccination in infants: A prospective cohort study. *J Family Med Prim Care*. 2015;4(3):384.
7. Roth A, Garly ML, Jensen H, Nielsen J, Aaby P. Bacillus Calmette-Guérin vaccination and infant mortality. *Expert Review of Vaccines*. 2006 Apr;5(2):277–93.
8. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. *The Lancet*. 1995 Nov;346(8986):1339–45.
9. Lalor MK, Ben-Smith A, Gorak-Stolinska P, Weir RE, Floyd S, Blitz R, et al. Population Differences in Immune Responses to Bacille Calmette-Guérin Vaccination in Infancy. *J INFECT DIS*. 2009 March 15;199(6):795–800.
10. Poyntz HC, Stylianou E, Griffiths KL, Marsay L, Checkley AM, McShane H. Non-tuberculous mycobacteria have diverse effects on BCG efficacy against *Mycobacterium tuberculosis*. *Tuberculosis (Edinb)*. 2014 May;94(3):226–37.
11. Storgaard L, Rodrigues A, Martins C, Nielsen BU, Ravn H, Benn CS, et al. Development of BCG Scar and Subsequent Morbidity and Mortality in Rural Guinea-Bissau. *Clin Infect Dis*. 2015 September 15;61(6):950–9.
12. Thomsen VØ, Andersen AB, Zhang X, Marrs CF, Yang Z, Kamper-Jørgensen

Z, et al. Effect of Sex, Age, and Race on the Clinical Presentation of Tuberculosis: A 15-Year Population-Based Study. *The American Journal of Tropical Medicine and Hygiene*. 2011 August 1;85(2):285–90.

13. Zelner JL, Murray MB, Becerra MC, Galea J, Lecca L, Calderon R, et al. Age-Specific Risks of Tuberculosis Infection From Household and Community Exposures and Opportunities for Interventions in a High-Burden Setting. *American Journal of Epidemiology*. 2014 October 15;180(8):853–61.

14. Snow KJ, Sismanidis C, Denholm J, Sawyer SM, Graham SM. The incidence of tuberculosis among adolescents and young adults: a global estimate. *Eur Respir J*. 2018 Feb;51(2):1702352.

15. Jaron B, Maranghi E, Leclerc C, Majlessi L. Effect of Attenuation of Treg during BCG Immunization on Anti-Mycobacterial Th1 Responses and Protection against *Mycobacterium tuberculosis*. Unutmaz D, editor. *PLoS ONE*. 2008 July 30;3(7):e2833.

16. Arnadottir T, Rieder HL, Trébuq A, Waaler HT. Guidelines for conducting tuberculin skin test surveys in high prevalence countries. *Tubercle and Lung Disease*. 1996 Jun;77:1–19.

17. Altet-Gomez N, De Souza-Galvao M, Latorre I, Mila C, Jimenez MA, Solsona J, et al. Diagnosing TB infection in children: analysis of discordances using in vitro tests and the tuberculin skin test. *European Respiratory Journal*. 2011 May 1;37(5):1166–74.

18. Kiwanuka JP. Interpretation of tuberculin skin-test results in the diagnosis of Tuberculosis in children. *Afr Health Sci*. 2005 Jun;5(2):152–6.

19. Nayak S, Acharjya B. Mantoux test and its interpretation. *Indian Dermatol Online J*. 2012;3(1):2.

20. Zahrani KA, Jahdali HA, Menzies D. Does Size Matter? Utility of Size of Tuberculin Reactions for the Diagnosis of Mycobacterial Disease. *Am J Respir Crit Care Med*. 2000 Oct;162(4):1419–22.

21. Babu S, Bhat SQ, Kumar NP, Kumaraswami V, Nutman TB. Regulatory T Cells Modulate Th17 Responses in Patients with Positive Tuberculin Skin Test Results. *J INFECT DIS*. 2010 Jan;201(1):20–31.

Conflict of Interest Statement








Manuscript title : The Correlation of Foxp3+ Gene and Regulatory T Cells with Scar BCG Formation among Children with Tuberculosis

The authors whose names are listed immediately below certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional





Journal Pre-proofs

relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

This statement is signed by all the authors to indicate agreement that the above information is true and correct

Author's name	Author's signature	Date
Dr. Farsida, MPH		October, 13th 2020
Prof.dr. Mochammad Hatta, Ph.D, Sp. MK(K)		October, 13th 2020
DR. Dr Ilhamjaya Patellongi, M.Kes		October, 13th 2020
DR. Dr. Prihantono, Sp.B.Onk (K)	 Dr. dr. prihantono, Sp ^h	October, 13th 2020
Prof. DR. Dr. Andi Asadul Islam, Sp.BS		October, 13th 2020
Prof. Dr. Rosdiana Natzir, Ph.D, Sp.Biok	 Rosdiana Natzir	October, 13th 2020
Prof. Dr. Muh. Nasrum Massi, Ph.D	 Dr. Muh. Nasrum Massi	October, 13th 2020

Journal Pre-proofs

Dr. Firdaus Hamid, Ph.D		October, 13th 2020
Dr. Dr. Andi Dwi Bahagia, Sp.A (K)		October, 13th 2020
dr. Rahmini Shabariyah, Sp.A		October, 13th 2020
dr. Rahma Ayu Larasati, M.Biomed		October, 13th 2020

1	Dr. Farsida, MPH	Conceptualization, Funding acquisition, Roles/Writing – original draft
2	Prof.dr. Mochammad Hatta, Ph.D, Sp. MK(K)	Conceptualization, Roles/Writing – original draft
3	DR. Dr Ilhamjaya Patellongi, M.Kes	Data curation, Methodology
4	DR. Dr. Prihantono, Sp.B.Onk (K)	Supervision
5	Prof. DR. Dr. Andi Asadul Islam, Sp.BS	Formal analysis, Validation
6	Prof. Dr. Rosdiana Natzir, Ph.D, Sp.Biok	Formal analysis, Validation
7	Prof. Dr. Muh. Nasrum Massi, Ph.D	Formal analysis, Validation
9	Dr. Firdaus Hamid, Ph.D	Formal analysis, Validation
8	Dr. Dr. Andi Dwi Bahagia, Sp.A (K)	Formal analysis, Validation
10	dr. Rahmini Shabariyah, Sp.A	Resources, Project administration

11	dr. Rahma Ayu Larasati, M.Biomed	Project administration , Writing – review & editing
----	----------------------------------	--

Journal Pre-proofs

ORIGINALITY REPORT

%**22**
SIMILARITY INDEX

%**22**
INTERNET SOURCES

%**23**
PUBLICATIONS

%**10**
STUDENT PAPERS

PRIMARY SOURCES

1 www.hindawi.com Internet Source %**3**

2 file.scirp.org Internet Source %**2**

3 docplayer.net Internet Source %**2**

4 C. S. Benn, A. Roth, M.-L. Garly, A. B. Fisker, F. Schaltz-Buchholzer, A. Timmermann, M. Berendsen, P. Aaby. "BCG scarring and improved child survival: a combined analysis of studies of BCG scarring", Journal of Internal Medicine, 2020
Publication %**2**

5 www.ncbi.nlm.nih.gov Internet Source %**2**

6 www.who.int Internet Source %**2**

7 Submitted to Southern New Hampshire University - Continuing Education %**2**

8

C. Lakshmi Prasanna, Satya Prakash P.,
Chowdary Babu M., Sagar V.. "BCG SCAR
FORMATION @ 3 MONTHS FOLLOWING BCG
VACCINATION IN TERM INFANTS @ ACSR
GOVT. MEDICAL COLLEGE, NELLORE,
ANDHRA PRADESH- A PROSPECTIVE
OBSERVATIONAL STUDY", Journal of
Evolution of Medical and Dental Sciences, 2019

Publication

%2

9

www.pubmedcentral.nih.gov

Internet Source

%1

10

mafiadoc.com

Internet Source

%1

11

academic.oup.com

Internet Source

%1

12

Babu, Subash, Sajid Q. Bhat, N. Pavan Kumar,
V. Kumaraswami, and Thomas B. Nutman.
"Regulatory T Cells Modulate Th17 Responses
in Patients with Positive Tuberculin Skin Test
Results", The Journal of Infectious Diseases,
2010.

Publication

%1

13

Submitted to Lourdes Hill College

Student Paper

%1

14

www.cignahealthbenefits.com

	Internet Source	% 1
15	www.jem.org Internet Source	% 1
16	Submitted to Grand Canyon University Student Paper	% 1
17	www.ajtmh.org Internet Source	% 1
18	Submitted to Al Maktoum Medical Library Student Paper	<% 1
19	journals.plos.org Internet Source	<% 1
20	dspace.nbu.gov.ua Internet Source	<% 1
21	www.jcdr.net Internet Source	<% 1
22	Megha Saroha, MMA Faridi, Prerna Batra, Iqbal Kaur, DK Dewan. "Immunogenicity and safety of early vs delayed BCG vaccination in moderately preterm (31–33 weeks) infants", Human Vaccines & Immunotherapeutics, 2015 Publication	<% 1
23	moam.info Internet Source	<% 1

24

C.J. Serrano, J.E. Castañeda-Delgado, J.L. Trujillo-Ochoa, R. González-Amaro, M.H. García-Hernández, J.A. Enciso-Moreno. "Regulatory T-cell subsets in response to specific Mycobacterium tuberculosis antigens in vitro distinguish among individuals with different QTF and TST reactivity", Clinical Immunology, 2015

Publication

<% 1

25

journals.lww.com

Internet Source

<% 1

26

apps.who.int

Internet Source

<% 1

EXCLUDE QUOTES ON

EXCLUDE ON

BIBLIOGRAPHY

EXCLUDE MATCHES < 5

WORDS